Discover more

“RayOne EMV is a solution that gives patients increased satisfaction with the least compromise in their quality of vision.”

Professor Graham Barrett,

Developer of RayOne EMV

How does RayOne EMV work?

RayOne EMV is a truly non-diffractive IOL which does not use light splitting technology like many IOLs which increase depth of focus, resulting in low levels of dysphotopsia, similar to standard monofocal lenses.1

RayOne EMV is the only patented aspheric IOL that induces controlled positive spherical aberration.

Compared to a lens with zero spherical aberration, the carefully controlled positive spherical aberration induced by RayOne EMV spreads light along the visual axis.

Centre region

Induced positive spherical aberration

Blended edge region

Reduced longitudinal spherical aberration designed to maintain visual acuity and constrast sensitivity under mesopic conditions.

With RayOne EMV Toric you can correct more of your patients, even those with significant corneal astigmatism

In a robust FDA IDE trial:11

Patients implanted with RayOne EMV Toric had a clinically significant reduction in residual cylinder, surpassing the FDA’s recommendation of 0.4 D.

RayOne EMV Toric provided consistently precise astigmatism correction with >85% of patients within ±0.5 D from Month 1 onwards.

 

 

  • Single piece IOL created from a homogeneous material free of microvacuoles1
  • Compressible material for delivery through a 2.2 mm micro incision2
  • Excellent handling characteristics with controlled unfolding within the capsular bag3
  • Low silicone oil adherence4
  • Excellent uveal biocompatibility5
  • Hydrophilic acrylic material with low inflammatory response6
  • 13 million Rayacryl hydrophilic IOL implantations

 

  1. Rayner. Data on File (RDTR 1937).
  2. Nanavaty M. et al. J Cataract Refract Surg 2017; 43:558-563.
  3. Data on file. Rayner. PMCF.
  4. McLoone E, Mahon G, Archer D, Best R. Br J Ophthalmol. 2001; 85:543-545.
  5. Tomlins PJ, Sivaraj RR, Rauz S, Denniston AK, Murray PI. J Cataract Refract Surg. 2014; 40:618-625.
  6. Rayner. Data on File.
  7. Mathew RG, Coombes AGA. Ophthalmic Surg Lasers Imaging. 2010 Nov-Dec; 41(6):651-5.
  • Proven rotational stability and centration2 with predictable, sustainable and accurate visual results.
  • Average offset of only 0.04 mm 1 to 6 months after surgery2
  • 1.36° mean IOL rotation 3 to 6 months after surgery2

  1. Outer haptics begin to take up the compression forces of post-operative capsule contraction
  2. Outer haptics engage the inner haptics
  3. Haptic tips gently meet the IOL optic and are effectively locked into position
1

Supplied in saline

2

True two-step system

3

Single handed plunger with minimal force required

4

1.65mm nozzle for 2.2mm incision

5

Unique Lock & Roll technology - rolls the lens
inside the injector for a single smooth movement

Peer2Peer | “My Next Ophthalmologist Needs No Introduction” with Dr Stonecipher (Ep2: Prof Barrett)

 

Peer2Peer | RayOne EMV US Billing Opportunities

RayOne EMV Toric

Indication: The RayOne EMV Toric (Model RAO210T) consists of the EMV Toric IOL (210T) preloaded within the RayOne injection system (RAO). The EMV Toric IOL is intended for primary implantation in the capsular bag of the eye for the visual correction of aphakia, in adult patients in whom a cataractous lens has been removed by phacoemulsification and providing reduction of residual refractive astigmatism in adult patients with greater than or equal to 1.00 diopter (D) of corneal astigmatism,compared to a monofocal IOL. The RayOne injection system is used to fold and assist in inserting the IOL into the eye.

RayOne EMV Toric FDA Trial Safety Data | Postoperative Findings

Table A provides a detailed comparison of observed adverse events versus the ISO 11979-7 safety grid. The results of adverse events analyses based on the consensus definitions as set forth by American Academy of Ophthalmology’s Task Force (Masket et al. Ophthalmology 2017) are shown below in Table B. All other ocular adverse events are listed in Table C. Unless otherwise specified, all percentages are based on the Safety Set or subjects implanted with the Toric IOL (N=117) and Monofocal IOL (N=116).

 

  1. Ferreira TB. Presented at ESCRS 2022 [Symposia].
  2. Rayner 2025, data on file (FDA IDE trial).

The safety and effectiveness of RayOne EMV Toric (RAO210T) has been demonstrated in an FDA IDE trial.

CAUTION: United States Federal Law restricts this device to sale and distribution by or on the order of a physician and its use is restricted to a properly licensed physician.

Published by Rayner.